RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0042-1756433
Malignant Hyperthermia Like Manifestations during Management of Refractory Status Epilepticus
Abstract
Management of refractory status epilepticus is challenging for a neurointensivist consequent to systemic complexities associated with various drugs and modalities involved in its treatment. We report one such case that manifested with multiple signs of malignant hyperthermia following use of isoflurane to control seizures. However, the delayed and random occurrence of the signs and negative genetic test report raises doubts regarding the final diagnosis. Delayed presentation of malignant hyperthermia has been reported earlier. Unavailability of dantrolene sodium handily is a major hurdle in treating such cases. We enumerate management of the patient in our intensive care unit.
Publikationsverlauf
Artikel online veröffentlicht:
12. Mai 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134 (Pt 10): 2802-2818
- 2 Firstenberg M, Abel E, Blais D, Andritsos M. Delayed malignant hyperthermia after routine coronary artery bypass. Ann Thorac Surg 2010; 89 (03) 947-948
- 3 Newmark JL, Voelkel M, Brandom BW, Wu J. Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient. Anesthesiology 2007; 107 (02) 350-353
- 4 Raut MS, Kar S, Maheshwari A. et al. Rare postoperative delayed malignant hyperthermia after off-pump coronary bypass surgery and brief review of literature. Ann Card Anaesth 2016; 19 (02) 357-362
- 5 Larach MG, Localio AR, Allen GC. et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80 (04) 771-779
- 6 Liu ST, Liu LF, Wang SY. Treatment of malignant hyperthermia without dantrolene in a 14-year-old boy. Chin Med J (Engl) 2017; 130 (06) 755-756
- 7 Koo BS, Kim YK, Kim SH, Lee JS, Kim YI. A suspected malignant hyperthermia managed without dantrolene sodium. Korean J Anesthesiol 2014; 67 (Suppl): S81-S82
- 8 Evans TJ, Parent CM, McGunigal MP. Atypical presentation of malignant hyperthermia. Anesthesiology 2002; 97 (02) 507-508
- 9 Ramanujam M, Gulati S, Tyagi A. Malignant hyperthermia: an Indian perspective. J Anaesthesiol Clin Pharmacol 2019; 35 (04) 557-558
- 10 Gupta PK, Hopkins PM. Diagnosis and management of malignant hyperthermia. BJA Educ 2017; 7: 249-254